Results for:(80 found)
Apr 18, 2012 1:29PM on Top StocksBy Trefis

The FDA adds warning about sexual side effects to Propecia, a drug used to treat baldness.

Apr 2, 2012 1:48PM on Top StocksBy Trefis

The Affordable Care Act implies a major reform in the public and private health insurance industry, which should increase demand for drugs and diagnostic equipment.

Feb 27, 2012 4:27PM on Top StocksBy Jim J. Jubak

The company faces a revenue loss as one of its blockbuster drugs, Singulair, loses patent protection this year.

Feb 24, 2012 3:29PM on Top StocksBy Jim J. Jubak

The already-healthy dividend from the energy company could get an increase with the acquisition of El Paso.

Feb 13, 2012 1:28PM on Top StocksBy MoneyShow.com

You can't get more solid than these picks from a defensive fund manager.

Feb 10, 2012 11:10AM on Top StocksBy TheStockAdvisors

All of these companies have boosted their payouts for 25 consecutive years.

Feb 8, 2012 10:22AM on Top StocksBy TheStockAdvisors

A breakup of the drugmaker into separate operating entities should unlock shareholder value.

Tags: ABT
Jan 17, 2012 10:41AM on Top StocksBy TheStockAdvisors

For income investors with a long-term horizon, here are 10 favorite dividend-paying blue chips.

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More